AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022)

AbCellera Biologics' Accumulated Depreciation history runs 3 years deep, the most recent figure standing at $18.5 million for Q4 2022.

• Quarterly Accumulated Depreciation rose 88.02% year-over-year to $18.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $18.5 million (up 88.02% YoY) and the FY2022 annual result came in at $18.5 million, up 88.02% from the prior year.
• Accumulated Depreciation was $18.5 million for Q4 2022 at AbCellera Biologics, up from $15.7 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $18.5 million in Q4 2022 and bottomed at $5.6 million in Q4 2020.
• A 3-year average of $10.7 million and a median of $9.8 million in 2021 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation soared 75.9% — and 2022, when it jumped 88.02%.
• AbCellera Biologics' Accumulated Depreciation stood at $5.6 million in 2020, then surged by 75.9% to $9.8 million in 2021, then soared by 88.02% to $18.5 million in 2022.
• Business Quant data shows ABCL's Accumulated Depreciation at $18.5 million in Q4 2022, $15.7 million in Q3 2022, and $13.2 million in Q2 2022.